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Impaired insulin-mediated suppression of hepatic
glucose production (HGP) plays a major role in the
pathogenesis of type 2 diabetes (T2D), yet themolec-
ular mechanism by which this occurs remains
unknown. Using a novel in vivo metabolomics
approach, we show that the major mechanism by
which insulin suppresses HGP is through reductions
in hepatic acetyl CoA by suppression of lipolysis in
white adipose tissue (WAT) leading to reductions in
pyruvate carboxylase flux. This mechanism was
confirmed inmice and ratswith genetic ablation of in-
sulin signaling and mice lacking adipose triglyceride
lipase. Insulin’s ability to suppress hepatic acetyl
CoA, PC activity, and lipolysis was lost in high-fat-
fed rats, a phenomenon reversible by IL-6 neutraliza-
tion and inducible by IL-6 infusion. Taken together,
these data identify WAT-derived hepatic acetyl CoA
as the main regulator of HGP by insulin and link it
to inflammation-induced hepatic insulin resistance
associated with obesity and T2D.
INTRODUCTION
The Centers for Disease Control predict that by the year 2050,
one in three Americans will suffer from type 2 diabetes (T2D)
(Boyle et al., 2010); therefore, efforts to understand and intervene
in the pathogenesis of the disease are urgently needed. Fasting
hyperglycemia, due to increased rates of hepatic gluconeogen-
esis, and the inability of insulin to suppress this process are the
hallmark of T2D, but the molecular mechanism for this alteration
is unknown (Kahn et al., 2014; Olefsky and Glass, 2010; Robbinset al., 2014; Samuel and Shulman, 2012). In this regard, mice
lacking Akt1, Akt2, and Foxo1 (TKO) (Lu et al., 2012), the
canonical insulin signaling proteins thought to regulate hepatic
glucose production (HGP), surprisingly do not show any defect
in insulin-mediated suppression of HGP.
We hypothesized that insulin’s ability to suppress lipolysis in
white adipose tissue (WAT) may be critical for the suppression
of HGP by reducing fatty acid flux to the liver resulting in
decreased hepatic acetyl CoA concentrations and decreased
pyruvate carboxylase (PC) activity, the first step in the conver-
sion of pyruvate to glucose. While hepatic acetyl CoA has been
previously shown to modulate PC activity in vitro (Barritt et al.,
1966; Cazzulo and Stoppani, 1968; Cooper and Benedict,
1966; Keech and Utter, 1963; Krebs et al., 1965), methodological
limitations stemming from acetyl CoA’s low concentrations and
rapid degradation ex vivo have prevented its measurement
in vivo.
We further hypothesized that increased hepatic acetyl CoA,
due to increased rates of WAT lipolysis, is responsible for
increased fasting HGP and reduced insulin-mediated suppres-
sion of HGP in high-fat-fed rodent models of diet-induced
obesity associated with hepatic insulin resistance and hypergly-
cemia. In this regard, inflammatory cytokines are well-estab-
lishedmediators of lipolysis (Fonseca-Alaniz et al., 2007; Savage
et al., 2005; Suganami and Ogawa, 2010), and protection from
inflammation-associated insulin resistance could explain the
preserved insulin sensitivity of macrophage-specific c-JUN
N-terminal kinase (m4JNK) knockout mice fed a high-fat diet
(Han et al., 2013).
To address these questions, we developed a novel liquid chro-
matography/tandemmass spectrometry (LC-MS/MS) technique
to measure hepatic acetyl CoA content from in situ freeze-
clamped liver within 10 s of intravenous euthanasia in awake,
unrestrained rats. These measurements were combined with
measurements of whole-body rates of lipolysis, assessed byCell 160, 745–758, February 12, 2015 ª2015 Elsevier Inc. 745
rates of [1,1,2,3,3-2H5] glycerol and [U-
13C] palmitate turnover,
combined with rates of glucose turnover assessed by [3-3H]
glucose before and during a hyperinsulinemic-euglycemic
clamp. Finally, we also performed additional studies to quantify
in vivo pyruvate carboxylase flux and relative contributions of
oxaloacetate and glycerol to hepatic gluconeogenesis using a
combined NMR-LC-MS/MS positional isotopomer approach
with [3-13C] lactate as a tracer. Using this comprehensive in vivo
metabolomics approach, we show that hepatic acetyl CoA is
the key regulator of hepatic insulin action in normal fasted,
free-ranging rodents in vivo and that fasting hyperglycemia
and insulin resistance in high-fat-fed rodents result from an inap-
propriate increase in hepatic acetyl CoA concentrations due to
macrophage-induced WAT lipolysis.
RESULTS
Insulin Suppression of Glucose Production Is
Temporally Associated with Suppression of Lipolysis
and Hepatic Acetyl CoA
In order to examine the respective roles of hepatic acetyl CoA
and glycerol turnover in the regulation of HGP by insulin, we
infused awake rats with insulin tomimic physiologic postprandial
insulin concentrations during a hyperinsulinemic-euglycemic
clamp and found that plasma non-esterified fatty acid (NEFA)
and glycerol concentrations were suppressed by 90% within
5 min, and HGP was suppressed by 70% within 10 min after
initiation of the insulin infusion as reflected by a rapid increase
in the plasma glucose specific activity (Figures 1A–1C; Figures
S1A–S1D). This reduction in HGP was associated with a 50%
reduction in hepatic acetyl CoA concentrations within 10 min
of the start of the insulin infusion as well as a 60% suppression
of whole-body glycerol and palmitate turnover at steady state
with no changes in plasma lactate, glucagon, or liver glycogen
concentrations (Figures 1D–1F and S1E–S1G). Therefore, these
data demonstrate that the major effect of insulin to suppress
HGP under these conditions was through suppression of hepatic
gluconeogenesis.
Clamping Hepatic Acetyl CoA and Whole-Body Glycerol
Turnover Abrogates Insulin Suppression of HGP
Based on the previous data, we next examined whether altering
hepatic acetyl CoA concentrations, and/or altering rates of
whole-body glycerol turnover, would change rates of HGP dur-
ing a hyperinsulinemic-euglycemic clamp. In order to modify he-
patic acetyl CoA concentrations, we infused sodium acetate at
increasing rates during a hyperinsulinemic-euglycemic clamp,
and observed a strong correlation between hepatic acetyl CoA
concentrations and both pyruvate carboxylase (PC) activity
(r2 = 0.85, p < 0.0001) and HGP (r2 = 0.68, p < 0.0001) during
the clamp, without any changes in liver glycogen content (Fig-
ures 1G–1I and S1H–S1M).
Likewise, in order to assess the potential contribution of insu-
lin-mediated suppression of glycerol turnover to insulin-medi-
ated suppression of HGP by a substrate-push mechanism, we
infused glycerol at increasing rates in awake rats during a hyper-
insulinemic-euglycemic clamp and observed a strong correla-
tion (r2 = 0.55, p < 0.0001) between rates of glycerol turnover746 Cell 160, 745–758, February 12, 2015 ª2015 Elsevier Inc.and rates of HGP, without any change in liver glycogen or acetyl
CoA (Figures 1J–1L and S1N–S1R). Taken together, these data
demonstrate that modulation of either hepatic acetyl CoA con-
centrations or glycerol turnover can independently modulate
rates of HGP during a hyperinsulinemic-euglycemic clamp.
In order to determine whether insulin-mediated suppression of
hepatic acetyl CoA concentrations and glycerol turnover were
responsible for insulin-mediated suppression of HGP, we co-
infused both acetate and glycerol to match hepatic acetyl CoA
concentrations and rates of glycerol turnover during a hyperinsu-
linemic-euglycemic clamp to those observed under basal condi-
tions (Figures 2A–2D; Figures S2A and S2B). Matching hepatic
acetyl CoA concentrations and whole-body glycerol turnover
rates to baseline levels completely abrogated insulin-mediated
suppression of PC flux and HGP, without any changes to plasma
glucagon or liver glycogen concentrations, or expression of glu-
coneogenic proteins in the liver (Figures 2E, 2F, and S2C–S2E).
Multiple regression analysis confirmed the linear relationships
betweenHGP and both liver acetyl CoA andwhole-body glycerol
turnover (p = 0.002 and p= 0.01, respectively). We next assessed
the relative contributions of oxaloacetate and glycerol conver-
sion to glucose before and during a clamp and found that the
suppression of hepatic gluconeogenesis could entirely be
ascribed to suppression of lipolysis, with 85%of the suppression
of HGP attributed to reduced conversion of oxaloacetate to
glucose and the remainder attributed to reduced conversion of
glycerol to glucose (Figure 2E).
Liver Akt1/Ak2/Foxo1 Knockout Mice Suppress
Lipolysis, Hepatic Acetyl CoA, and HGP Normally, but
Acetate and Glycerol Infusion Abrogates Insulin
Suppression of HGP
TKO mice exhibited no alterations in basal or insulin-mediated
reductions in rates of HGP before and during a hyperinsuline-
mic-euglycemic clamp despite clear knockdown of Akt1/Akt2
and Foxo1 protein concentrations in liver (Lu et al., 2012) (Fig-
ure 3A; Figures S3A–S3C). Consistent with our data in awake
rats, hepatic acetyl CoA concentrations, PC activity, and rates
of whole-body lipolysis were similarly suppressed in WT and
TKO mice during the hyperinsulinemic-euglycemic clamp,
without any change in hepatic glycogen content (Figures 3B–
3D and S3D–S3G). Furthermore, co-infusion of acetate and glyc-
erol to maintain basal hepatic acetyl CoA concentrations and
basal rates of glycerol turnover, fully abrogated insulin’s ability
to suppress HGP during the hyperinsulinemic-euglycemic clamp
(Figures 3B–3D).
Inhibition of Lipolysis Decreases Hepatic Acetyl CoA
and HGP in Insulin Receptor Antisense Oligonucleotide-
Treated Rats Lacking Insulin Receptor in Liver and Fat
In order to more directly examine the putative requirement for
suppression of lipolysis to permit suppression of HGP, we
treated rats with a 20-O-methoxyethyl chimeric antisense oligo-
nucleotide to knock down the insulin receptor (IR ASO) in liver
and adipose tissue (Figure 3E). IR ASO-treated rats displayed
severe insulin resistance manifested by failure to suppress lipol-
ysis, hepatic acetyl CoA, and HGP during a hyperinsulinemic-
euglycemic clamp; however, all of these effects were abrogated
Figure 1. Rapid Suppression of Hepatic Glucose Production Rates Is Temporally Associated with a Parallel Rapid Suppression of Lipolysis
(A) Hepatic glucose production measured by the Steele equation (Steele, 1959). Comparisons by ANOVA with Bonferroni’s multiple comparisons test. ****p <
0.0001 versus time 0.
(B and C) Plasma non-esterified fatty acid (NEFA) and glycerol concentrations during the hyperinsulinemic-euglycemic clamp. In (A)–(C), n = 6 per time point.
(D) Hepatic acetyl CoA concentrations. n = 4 per time point. *p < 0.01, **p < 0.01 versus time 0 by the two-tailed unpaired Student’s t test.
(E and F) Whole-body palmitate and glycerol turnover rates.
(G–I) Liver acetyl CoA concentrations, hepatic glucose production, and pyruvate carboxylase activity in rats undergoing a hyperinsulinemic-euglycemic clamp
with co-infusion of acetate. In (G)–(L), n = 4 per group.
(J–L) Plasma glycerol concentrations, whole-body glycerol turnover, and hepatic glucose production in rats undergoing a hyperinsulinemic-euglycemic clamp
with co-infusion of glycerol.
In (G)–(L), n = 4 per group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus 0 mmol/(kg-min). In all panels, data are mean ± SEM. See also Figure S1.by administration of atglistatin, a specific inhibitor of adipose tri-
glyceride lipase (Figures 3F–3H and S3H–S3L), attributing the
suppression of HGP to the inhibition of lipolysis and subsequent
reductions in hepatic acetyl CoA and PC activity in both control
and IR knockdown rats.High-Fat-Fed Rats Manifest Increased Rates of HGP and
Hepatic Insulin Resistance Associated with Increased
Lipolysis and Increased Hepatic Acetyl CoA
In order to understand the potential role of hepatic acetyl
CoA in the pathogenesis of fasting and postprandialCell 160, 745–758, February 12, 2015 ª2015 Elsevier Inc. 747
Figure 2. Normalizing Hepatic Acetyl CoA Concentrations and Whole-Body Glycerol Turnover to Baseline Levels in the Hyperinsulinemic-
Euglycemic Clamp Abrogates Insulin’s Ability to Suppress Hepatic Glucose Production
(A) Liver acetyl CoA content.
(B) Whole-body glycerol turnover.
(C) Plasma glycerol concentrations.
(D) Glucose infusion rate.
(E) Hepatic glucose production from oxaloacetate (lower bars) and glycerol (upper bars).
(F) PC activity.
In all panels, ****p < 0.0001 versus basal, xxxxp < 0.0001 versus hyperinsulinemic-euglycemic clamp. n = 6 per group. Data are mean ± SEM. Comparisons by
ANOVA with Bonferroni’s multiple comparisons test. See also Figure S2.hyperglycemia in a chronic high-fat-fed rodent model of
insulin resistance associated with inflammation, we fed male
Sprague-Dawley rats a high-fat diet for 4 weeks and observed,
as expected, increases in fasting plasma glucose, insulin,
and non-esterified fatty acid (NEFA) concentrations without
any increases in plasma glucagon concentrations (Figures
S4A–S4D). Fasting hyperglycemia in the HFD group was
associated with a 25% increase in rates of basal HGP, 60%
of which was derived from increases in hepatic pyruvate
carboxylase flux, and 40% from increased conversion of
glycerol to glucose. In chow-fed rats, insulin suppressed748 Cell 160, 745–758, February 12, 2015 ª2015 Elsevier Inc.HGP in a hyperinsulinemic-euglycemic clamp, 85% through
reductions in flux through hepatic pyruvate carboxylase,
and 15% through reductions in the contribution of glyc-
erol to glucose (Figure 4A; Figures S4E–S4G). How-
ever, in the high-fat-fed rats, insulin failed to suppress HGP
during a hyperinsulinemic-euglycemic clamp associated with
increased basal and clamped acetyl CoA and PC activity,
and with higher rates of lipolysis both before and during the
hyperinsulinemic-euglycemic clamp in the HFD group, without
any differences in gluconeogenic protein expression (Figures
4B–4E, S4H, and S4I).
Figure 3. Suppression of Lipolysis Results in Decreased Hepatic Acetyl CoA Concentrations and Suppression of Hepatic Glucose
Production Independent of Hepatic Insulin Signaling
(A) Protein expression in Akt1 and 2 and Foxo1 knockout mice.
(B) Hepatic glucose production. In all panels, black bars, basal; white bars, clamp; and gray bars, clamp+acetate+glycerol.
(C) Hepatic acetyl CoA concentrations.
(D) Hepatic pyruvate carboxylase activity. In (B)–(D), *p < 0.05, **p < 0.01, ***p < 0.001 versus basal, xp < 0.05, xxp < 0.01, xxxp < 0.001 versus hyperinsulinemic-
euglycemic clamp by ANOVA. Data are mean ± SEM of n = 5 per group (basal), 8–9 per group (hyperinsulinemic-euglycemic clamp), and 3–4 per group
(hyperinsulinemic-euglycemic clamp + acetate + glycerol).
(E) Protein expression in insulin receptor knockdown rats.
(F) Hepatic glucose production. Atglistatin-treated rats were given 600 mmol/kg.
(G) Liver acetyl CoA.
(H) Hepatic PC activity.
In (F)–(H), ****p < 0.0001 versus basal, xxxxp < 0.0001 versus hyperinsulinemic-euglycemic clamp by ANOVA. Data are mean ± SEM of n = 6 per group. See also
Figure S3.Increased Lipolysis Plays a Key Role in Excess Hepatic
Gluconeogenesis in High-Fat-Fed Rodents
In order to confirm whether excess lipolysis causes excess HGP
in diet-induced obesity, we studied high-fat-fed adipose-
specific adipose triglyceride lipase (ATGL) knockoutmice. These
mice exhibited a 5-fold increase in insulin’s ability to suppress
HGP in a hyperinsulinemic-euglycemic clamp, associated with
40%–60% reductions in hepatic acetyl CoA, PC activity, and
whole-body palmitate and glycerol turnover during the clamp
(Figures 4F–4J; Figures S5J–S5M).High-Fat-Fed Rats Manifest Insulin Resistance in White
Adipose Tissue
To determine the primary source(s) of the excess lipolysis in high-
fat-fed rodents, we measured the ratio of tissue to plasma 13C16
palmitate in rats infused with 13C16 palmitate. The ratio of tissue
to plasma 13C16 palmitate was 100% in liver, skeletal muscle,
and kidney, but only 65% in WAT, confirming WAT as the
source of the majority of fatty acids derived from lipolysis in
both the basal and clamped state (FiguresS4NandS4O). In addi-
tion, in order to determine the proportion of acetyl CoA derivedCell 160, 745–758, February 12, 2015 ª2015 Elsevier Inc. 749
Figure 4. Four Weeks of High-Fat Feeding Increases Hepatic Glucose Production as a Result of Increased Lipolysis
(A) Hepatic glucose production from oxaloacetate and glycerol.
(B and C) Liver acetyl CoA and PC activity.
(D and E) Whole-body palmitate and glycerol turnover.
In (A)–(E), data are mean ± SEM of n = 6 per group. *p < 0.05, **p < 0.01, ****p < 0.0001 versus chow-fed, basal rats by the two-tailed unpaired Student’s t test.
(F) Hepatic glucose production in basal and clamped high-fat-fed adipose-specific ATGL knockout mice.
(G and H) Liver acetyl CoA and PC activity.
(I and J) Whole-body palmitate and glycerol turnover.
In (F)–(J), data are mean ± SEM of n = 8 per group. ***p < 0.001, ****p < 0.0001 versus basal WT, ####p < 0.0001 versus basal ATGL knockouts by the two-tailed
unpaired Student’s t test. See also Figures S4 and S5.
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from palmitate, wemeasured the ratio of hepatic 13C2 acetyl CoA
to 13C16 palmitate in rats infused with
13C16 palmitate. In both
chow and high-fat-fed rats, under both basal and clamped con-
ditions, the enrichment of hepatic acetyl CoA was approximately
75% of palmitate, showing that a large proportion of hepatic
acetyl CoA is derived from palmitate in vivo (Figure S4P).
WAT insulin resistance in high-fat-fed rats was reflected in the
failure of insulin to stimulateAkt phosphorylation, glucoseuptake,
or lipogenesis inWAT (Figures S4Q–S4S). The increased lipolysis
wasassociatedwitha largermeandiameter of largeadipocytes, a
reduced number of large adipocytes (Kursawe et al., 2010), and a
doubling in WAT comparative gene identification-58 (CGI-58)
protein expression (Yamaguchi et al., 2004, 2007), without any
other changes in lipolytic or insulin signaling proteins in WAT,
liver glycogen or ceramide content, plasma lactate, FGF-21,
adiponectin, or lipolytic hormones (Figures S4T–S4EE). Liver
concentrations of other putative mediators of gluconeogenesis,
including the ratios of ATP to ADP, ATP to AMP, NAD+ to
NADH, and four TCA cycle intermediates were also unchanged
in high-fat-fed or clamped rats (Figures S5A–S5G).
Inhibition of Adipose Triglyceride Lipase Normalizes
Hepatic Acetyl CoA Content, PC Activity, HGP, and
Plasma Glucose Concentrations in High-Fat-Fed Rats
To determine whether increased rates ofWAT lipolysis leading to
increased hepatic acetyl CoA concentrations and PC activity in
HFD rats were responsible for the increased rates of HGP in
the basal state and the failure of insulin to suppress HGP during
the hyperinsulinemic-euglycemic clamp, we treated rats with at-
glistatin. Atglistatin treatment normalized fasting plasma glucose
and insulin concentrations and HGP by lowering WAT lipolysis,
liver acetyl CoA concentrations, and PC activity without affecting
plasma glucagon concentrations (Figures S5H–S5Q). These
data demonstrate a critical but rapidly reversible role for
WAT lipolysis driving increases in hepatic acetyl CoA and PC ac-
tivity resulting in hyperglycemia in high-fat-fed, insulin-resistant
rats.
To further examine the role of increases in hepatic acetyl CoA
in causing excess gluconeogenesis, we treated chow and high-
fat-fed rats with etomoxir, a potent inhibitor of carnitine palmi-
toyltransferase-1 (CPT-1). Consistent with the previous studies
demonstrating a strong relationship between hepatic acetyl
CoA concentration and rates of HGP, etomoxir treatment re-
sulted in reductions in hepatic acetyl CoA content, which was
associated with lower fasting plasma glucose and insulin con-
centrations, reduced rates of HGP, and reduced PC activity
without any change in liver glycogen content (Figures S5R–
S5W). These data further support the hypothesis that hepatic
acetyl CoA is a key regulator of hepatic gluconeogenesis and
HGP in normal, fasting rodents.
Adipose Tissue Inflammation Increases Hepatic Acetyl
CoAContent and PC Activity and Causes Hepatic Insulin
Resistance in HFD Rats
Next, we sought to determine the reason for the increased rates
of lipolysis in HFD rats. In the absence of any changes in lipolytic
hormone (growth hormone, epinephrine, norepinephrine, corti-
costerone) concentrations, we hypothesized that adipose tissueinflammation may play an important role in this process (Man-
teiga et al., 2013; Olefsky and Glass, 2010; Robbins et al.,
2014). Consistent with this hypothesis, we observed a doubling
of plasma and WAT macrophage interleukin-6 (IL-6) concentra-
tions, without changes in any other inflammatory mediators (Fig-
ures 5A, 5B, and S6A). We confirmed white adipose tissue as a
target of IL-6 by incubating WAT with the concentrations of
IL-6 measured in plasma in vivo (15 and 25 nM) and observed
a 50% increase in fatty acid release into the media over 24 hr
(Figure S6B). Increases in granulocyte macrophage colony stim-
ulating factor (GM-CSF) in both plasma and WAT may be
responsible for attracting increased macrophages to WAT in
high-fat-fed rats and/or inducing their proliferation, and IL-6
has been shown to stimulate lipolysis through activation of the
JAK-Stat signaling pathway (Cernkovich et al., 2008; Guschin
et al., 1995; Lu¨tticken et al., 1994; Stahl et al., 1994). A modest
20% increase in WAT tumor necrosis factor-a (TNF-a) was also
observed, consistent with increased macrophage activation in
HFD rats (Figures S6C–S6D). Time-course studies with varying
periods of HFD treatment confirmed a temporal relationship be-
tween fasting plasma glucose, insulin, and NEFA concentrations
and both plasma and WAT macrophage IL-6 and GM-CSF con-
centrations (Figures S6E–S6K), with each increasing between
days 6 and 8. In addition, by 6 days of high-fat feeding, adipo-
cytes had begun to exhibit hypertrophy (Figure S6L).
In order to directly assess the role of excess IL-6 in promoting
increased lipolysis,we treatedHFDratswithamonoclonalneutral-
izing antibody to IL-6 (Figure S6M). Neutralizing IL-6 in HFD rats
reduced plasma glucose, NEFA, glycerol, and insulin concentra-
tions to normal levels without any change in plasma glucagon
concentrations (Figures S6N–S6S). By lowering rates of lipolysis
and reducing hepatic acetyl CoA concentrations, anti-IL-6 treat-
ment resulted in a 50% reduction in hepatic PC activity and
normalized rates of HGP in the HFD rat, without affecting macro-
phage TNF-a concentrations (Figures 5C–5F and S6T–S6V).
IL-6 Infusion Induces Hepatic Insulin Resistance
through Increased Adipose Tissue Lipolysis and
Increased Hepatic Acetyl CoA Content, PC Activity,
and HGP
In order to directly examine the role of IL-6 inmediating increased
HGP through increased lipolysis, hepatic acetyl CoA content,
and PC activity, we performed a 4 hr intra-arterial infusion of re-
combinant IL-6 in control rats (Figure S6W). We found that an
infusion of IL-6 caused an increase in plasma glucose, NEFA,
and insulin concentrations, whichwere associatedwith amarked
increase in rates ofwhole-body lipolysis. These increases in rates
of lipolysis were associated with increases in HGP, which could
be attributed to a doubling in hepatic acetyl CoA content and
an 80% increase in hepatic PC activity without any change in
plasma glucagon concentrations (Figures 5G–5J and S6X–
S6EE). However, these effects were fully abrogated by ATGL
inhibition. The induction of lipolysis in IL-6-infused rats was asso-
ciatedwith an increase in expression of CGI-58, a potent co-acti-
vator of ATGL, in WAT. These data suggest that IL-6 stimulation
of lipolysis may be attributed in part to IL-6-induced increases in
WAT CGI-58 concentrations (Figure S6FF), highlighting a poten-
tial novel role for CGI-58 in inflammation-induced increases inCell 160, 745–758, February 12, 2015 ª2015 Elsevier Inc. 751
Figure 5. Increases in Plasma Interleukin-6
Concentrations Cause Hyperglycemia in
High-Fat-Fed Rats
(A and B) IL-6 concentrations in plasma and white
adipose tissue macrophages.
(C–F) Hepatic glucose production, PC activity,
liver acetyl CoA, and whole-body palmitate turn-
over in high-fat-fed rats treated with an IL-6-
neutralizing antibody.
(G and H) Hepatic glucose production, liver PC
activity, hepatic acetyl CoA, and whole-body
palmitate turnover in control rats treated with or
without IL-6 or IL-6 and atglistatin (200 mmol/kg).
In all panels, data are mean ± SEM of n = 6 per
group. Comparisons by the two-tailed unpaired
Student’s t test (A–E) or by ANOVA with Bonfer-
roni’s multiple comparisons test (F–H). *p < 0.05,
**p < 0.01, ***p < 0.001 versus controls; xxp < 0.01,
xxxp < 0.001 versus chow-fed, IL-6-infused rats.
See also Figure S6.WAT lipolysis in insulin-resistant rats. Taken together, these data
are consistent with the hypothesis that local production of IL-6
from macrophages in WAT promotes increased lipolysis leading
to increased hepatic acetyl CoA content, PC activity, HGP, and
hyperglycemia in high-fat-fed rodents.
Macrophage-Specific JNK Knockout Mice Are
Protected from Diet-Induced Insulin Resistance
In order to examine whether local production of IL-6, from mac-
rophages in WAT, promotes increased lipolysis, hepatic acetyl
CoA content, PC activity, HGP, and hyperglycemia in high-fat-
fed rodents, we next examined whether this mechanism would
explain why m4JNK KO mice, which have strikingly low plasma752 Cell 160, 745–758, February 12, 2015 ª2015 Elsevier Inc.and WAT macrophage IL-6 concentra-
tions (Figures 6A and 6B), are protected
from high-fat diet-induced hepatic insulin
resistance. We found that macrophage-
specific m4JNK KO mice exhibited
improved suppression of HGP during
the hyperinsulinemic-euglycemic clamp,
which was associated with reductions
in clamped glycerol and palmitate turn-
over, hepatic acetyl CoA content, and
hepatic PC activity (Figures 6C–6H and
S7A–S7C). All of these effects were
abrogated by infusion of IL-6 to
match plasma IL-6 concentrations in
the m4JNK knockouts to the wild-type
group, demonstrating a critical role for
IL-6-induced WAT lipolysis in mediating
hepatic insulin resistance in high-fat-
fed mice.
Obese Insulin-Resistant
Adolescents Display Increased
Lipolysis and Increased WAT IL-6
In order to determine whether our find-
ings in rats would translate to humans,we measured rates of HGP and lipolysis in obese insulin-
resistant adolescents. Compared to weight-matched obese
insulin-sensitive control subjects, insulin-resistant subjects dis-
played fasting hyperglycemia and hyperinsulinemia, which
were associated with increased rates of HGP, impaired
insulin-mediated suppression of lipolysis and impaired insulin-
mediated suppression of HGP. Impaired insulin suppression
of lipolysis was associated with an increased diameter of large
adipocytes and increased macrophage infiltration into the
subcutaneous white adipose tissue (Figures 7A–7I; Table S1).
Consistent with our findings in insulin-resistant high-fat-fed
rodents, insulin-resistant obese adolescents displayed in-
creased plasma IL-6 concentrations, and an approximately
Figure 6. Mice Lacking JNK in Macrophages Are Protected from Diet-Induced Hepatic Insulin Resistance
(A and B) Plasma and WAT macrophage IL-6 concentrations.
(C) Glucose infusion rate to maintain euglycemia during a hyperinsulinemic-euglycemic clamp.
(D) Liver acetyl CoA concentrations.
(E) Hepatic glucose production.
(F) Liver PC activity.
(G and H) Whole-body palmitate and glycerol turnover.
**p < 0.01, ***p < 0.001, ****p < 0.0001 versus basal mice; xp < 0.05, xxxp < 0.001, xxxxp < 0.0001 versus wild-type, clampedmice. Data are mean ± SEM of n = 10
(WT), 8 (m4JNK KO), or 10 (m4JNK KO+IL-6) per group. The groups were compared by ANOVA with Bonferroni’s multiple comparisons test. See also Figure S7.50% increase in IL-6 concentrations in WAT, which were more
than 20 times higher than plasma IL-6 concentrations (Figures
7J and 7K). Similar to the HFD rats, the increased rates of lipol-ysis and HGP in obese insulin-resistant adolescents were
associated with increased CGI-58 protein expression in WAT
(Figure 7L).Cell 160, 745–758, February 12, 2015 ª2015 Elsevier Inc. 753
Figure 7. Insulin-Resistant Obese Adolescents Have Increased Lipolysis and Impaired Suppression of HGP Associated with Increased WAT
IL-6 Concentrations
(A and B) Fasting and 2-hr post-challenge plasma glucose.
(C) Fasting plasma insulin.
(D) HOMA.
(E) Hepatic glucose production. Closed bars, basal; open bars, hyperinsulinemic-euglycemic clamp.
(F) Fasting NEFA.
(G) Suppression of glycerol turnover in the clamp.
(H) Mean diameter of large adipocytes.
(I) WAT macrophage counts.
(J and K) Plasma and WAT IL-6 concentrations.
(L) WAT CGI-58 protein.
Data are the mean ± SEM of 9–21 controls and 15–39 insulin-resistant subjects. Comparisons were made by the two-tailed unpaired Student’s t test. See also
Table S1.DISCUSSION
Suppression of HGP by insulin is critical for maintenance of
normal glucose homeostasis and alterations in this process
play a major role in the pathogenesis of T2D; however, the
molecular mechanism by which insulin suppresses HGP has re-754 Cell 160, 745–758, February 12, 2015 ª2015 Elsevier Inc.mained elusive and has been attributed to direct actions of insu-
lin on liver (Edgerton et al., 2009; Hepp, 1977; Pilkis andGranner,
1992) and indirect effects of insulin on brain (Hill et al., 2010; Jor-
dan et al., 2010; Lin et al., 2010; Obici et al., 2002; Schwartz et al.,
2013) and adipocyte (Lewis et al., 1996; Rebrin et al., 1996).
The canonical signaling pathway by which insulin has been
postulated to directly inhibit hepatic gluconeogenesis is through
activation of Akt, resulting in suppression of gluconeogenic pro-
tein expression by phosphorylation and exclusion of Forkhead
box (Foxo1) from the nucleus of the hepatocyte, and consequent
transcription-mediated reduction in hepatic gluconeogenesis
(Haeusler et al., 2014). However, the finding that triple knockout
mice lacking Akt 1 and Akt2 and Foxo1 in liver have normal sup-
pression of HGP during a hyperinsulinemic-euglycemic clamp
(Lu et al., 2012) poses considerable challenges to this paradigm.
Furthermore, insulin suppresses HGPwithin minutes of adminis-
tration in vivo, which can unlikely be explained by transcription-
ally mediated processes.
To explain this apparent paradox, we hypothesized that insu-
lin’s ability to suppress lipolysis in WAT may be critical for the
suppression of HGP by reducing fatty acid flux to the liver result-
ing in decreased hepatic acetyl CoA concentrations and
decreased PC activity resulting in decreased conversion of pyru-
vate to glucose. While hepatic acetyl CoA has been long known
to modulate pyruvate carboxylase activity in vitro (Barritt et al.,
1966; Cazzulo and Stoppani, 1968; Cooper and Benedict,
1966; Keech and Utter, 1963; Krebs et al., 1965), methodological
limitations stemming from acetyl CoA’s low hepatocellular con-
centrations and rapid degradation ex vivo have prevented its
measurement in vivo. Additionally, Chisholm et al. were not
able to demonstrate any direct effect of insulin on pyruvate
carboxylase activity in isolated hepatocytes (Chisholm et al.,
1983), begging the question of whether a hepatocyte-autono-
mous process is primarily responsible for insulin-mediated sup-
pression of PC activity and hepatic glucose production.
In order to examine this hypothesis, we developed a compre-
hensive metabolomics flux approach to simultaneously mea-
sure whole-body rates of lipolysis, glucose turnover, and intra-
hepatic fluxes as well as hepatic acetyl CoA content in rapidly
freeze-clamped livers. Using this approach, we demonstrate
that hepatic acetyl CoA content is a key regulator of
HGP and that an insulin-mediated reduction of hepatic acetyl
CoA concentrations, through inhibition of WAT lipolysis, is the
major mechanism by which insulin suppresses HGP in vivo.
While the ability of insulin to suppress HGP through an
indirect mechanism was postulated by Levine and Fritz more
than 50 years ago, the molecular mechanism regarding this
effect has remained elusive. These are the first studies, to our
knowledge, that demonstrate insulin regulation of pyruvate
carboxylase activity through modulation of hepatic acetyl CoA
concentrations and demonstrate that this mechanism is
responsible for insulin suppression of hepatic glucose produc-
tion in vivo. Furthermore, these data identify the mechanism
by which mice lacking the canonical hepatic insulin signaling
factors (Akt1, Akt2, Foxo1) are able to suppress HGP normally
and explain the enigmatic inability of insulin to suppress
hepatic glucose production in isolated hepatocyte preparations
(Lu et al., 2012).
We next examined whether increased hepatic acetyl CoA con-
centrations might be responsible for increased rates of hepatic
glucose production in insulin resistance andmight link inflamma-
tion and macrophage-induced lipolysis in WAT with fasting and
postprandial hyperglycemia through a similar mechanism. While
lipid-induced insulin resistance occurs early in the pathogenesisof T2D and can be dissociated from inflammation at this
stage, a key question arises as to identification of the factor(s)
that promotes the progression from ectopic lipid-induced in-
sulin resistance to impaired glucose tolerance and fasting hyper-
glycemia (Shulman, 2014). The classic view of this process
implicates impaired pancreatic b-cell and a-cell function along
with inflammation in this transition where the former leads to
increased hepatic gluconeogenic gene transcription and the
latter inhibits insulin action through the release of cytokines
and adipocytokines, which, in turn, leads to inhibition of insulin
signaling and increased hepatic gluconeogenic protein expres-
sion through activation of the NF-kB/JNK/ceramide biosynthetic
pathways (Olefsky and Glass, 2010). In this study, we explored
an alternative hypothesis in which progression to fasting hyper-
glycemia occurs throughmacrophage-inducedWAT lipolysis re-
sulting in increased hepatic pyruvate carboxylase activity
through increases in hepatic acetyl CoA content and increased
conversion of glycerol to glucose. Consistent with this hypothe-
sis, we show that high-fat-fed rats manifested a 2-fold increase
in plasma andWAT IL-6 concentrations, which caused hypergly-
cemia by increasing lipolysis, hepatic acetyl CoA, and HGP both
before and during a hyperinsulinemic-euglycemic clamp. Infu-
sions of IL-6 and treatment of high-fat-fed rats with an IL-6-
neutralizing antibody demonstrate that IL-6 is both necessary
and sufficient to induce hyperglycemia in the rat. These findings
were validated genetically in adipose-specific ATGL knockout
mice and m4JNK knockout mice, which were protected from
high-fat feeding-induced hepatic insulin resistance due to reduc-
tions in WAT lipolysis leading to decreased hepatic acetyl CoA
content, decreased PC activity, and decreased rates of HGP
during a hyperinsulinemic-euglycemic clamp.
Finally, we show these results translate to humans by
demonstrating that WAT inflammation is associated with
increased IL-6 concentrations in WAT, increased rates of lipol-
ysis, increased rates of HGP, and hepatic insulin resistance
assessed by a hyperinsulinemic-euglycemic clamp in obese in-
sulin-resistant adolescents. These results are consistent with
previous studies, which have observed that increased plasma
IL-6 concentrations are strong predictors of insulin resistance
in humans (Fernandez-Real et al., 2001; Glund et al., 2007;
Kado et al., 1999; Mohamed-Ali et al., 1997; Petersen et al.,
2006; Pickup et al., 1997; Steptoe et al., 2014; Straub et al.,
2000; Yuen et al., 2009).
Taken together, these data demonstrate that allosteric regu-
lation of pyruvate carboxylase activity by hepatic acetyl CoA,
through insulin suppression of WAT lipolysis, is a critical factor
in the regulation of hepatic glucose production by insulin in vivo.
Furthermore, these studies demonstrate that macrophage-
induced WAT lipolysis leading to increased hepatic acetyl
CoA content and increased pyruvate carboxylase activity/flux
is a key molecular mechanism linking WAT inflammation to
both fasting and postprandial hyperglycemia in T2D. These
data explain insulin’s inability to suppress hepatic glucose pro-
duction in high-fat-fed rodent models of diet-induced obesity
and hepatic insulin resistance independent of transcriptional
regulation of gluconeogenic enzymes or alterations in hepatic
glycogen metabolism and also explain recent studies that
find no relationship between hepatic gluconeogenic proteinCell 160, 745–758, February 12, 2015 ª2015 Elsevier Inc. 755
expression and fasting hyperglycemia in obese humans (Kuma-
shiro et al., 2011). These data also challenge the canonical view
of inflammation-mediated hepatic insulin resistance through
alterations in circulating cytokines, which, in turn, lead to
inhibition of hepatic insulin signaling and increased hepatic glu-
coneogenic protein transcription through activation of the
NF-kB/JNK/ceramide biosynthetic pathways. Finally, these re-
sults have important clinical implications for the pathogenesis
of T2D by linking inflammation and macrophage-induced WAT
lipolysis leading to increased hepatic acetyl CoA concentrations
and increased PC flux resulting in fasting and postprandial
hyperglycemia and identify macrophage-induced WAT lipolysis
and hepatic acetyl CoA as a novel potential therapeutic target
for T2D.
EXPERIMENTAL PROCEDURES
Animal Studies
Rodent protocols were approved by the International Animal Care and Use
Committees at the institutions at which the animals were housed (Yale Univer-
sity, the University of Pennsylvania, and the University of Massachusetts).
Additional information about the animal models is provided in Extended Exper-
imental Procedures.
Basal and Hyperinsulinemic-Euglycemic Clamp Studies
Basal infusion and hyperinsulinemic-euglycemic clamp studies were used to
assess whole-body and hepatic insulin sensitivity as described in the
Extended Experimental Procedures.
Acute Suppression of Hepatic Gluconeogenesis
To assess insulin’s acute ability to suppress gluconeogenesis, chow-fed rats
were infused with [3H] glucose (0.1 mCi/min) for 120 min. Blood samples were
taken at 100, 110, and 120 min to assess basal glucose turnover. At 120 min,
a 20-min insulin infusion was initiated (20 mU 3 kg1 prime, 2 mU 3 kg1 3
min1 for the duration of the study). Blood samples (100 ml) were taken every
3 min during the insulin infusion, and specific activity was measured using a
scintillation counter.
Variable Glycerol and Acetate Infusions
Sodium acetate was infused intra-arterially in rats at infusion rates 0, 130, 195,
260, or 390 mmol 3 kg1 3 min1. [3-3H] glucose was co-infused and blood
and livers obtained as above. In a separate group of rats, [1,1,2,3,3-d5] glycerol
was infused at infusion rates 0, 10, 30, 50, or 70 mmol 3 kg1 3 min1
for 120 min. Glycerol turnover and concentrations were measured by gas
chromatography/mass spectrometry (GC/MS) as described below. In the
studies in which acetate and glycerol were co-infused during the clamp to
abrogate insulin-mediated suppression of hepatic glucose production,
the infusion rates selected were 195 mmol 3 kg1 3 min1 acetate and
10 mmol 3 kg1 3 min1 glycerol.
Measurement of Glucose, Fatty Acid, and Glycerol Turnover
Whole-body glucose turnover was calculated as the ratio of the [3-3H] glucose
infusion rate to the specific activity of plasma glucose at the end of the 120min
infusion. Endogenous glucose production represents the difference between
the glucose infusion rate and the rate of glucose appearance. The liver was
assumed to contribute 90% of whole-body glucose production based on
our prior studies (Perry et al., 2014). Hepatic flux rates were calculated as
we describe in Extended Experimental Procedures. [U-13C] palmitate (Beylot
et al., 1993) and [1,1,2,3,3-d5] glycerol (Previs et al., 1999) enrichment and total
glycerol concentration were measured by GC/MS as previously reported, and
turnover was calculated using the formula
Turnover =

13C tracer enrichment
13C plasma enrichment
 1

 Infusion rate:756 Cell 160, 745–758, February 12, 2015 ª2015 Elsevier Inc.ATGL Inhibition
Groups of overnight fasted chow and high-fat-fed rats were treated with intra-
peritoneal injections of atglistatin (200 or 600 mmol/kg, as designated in the
text, XcessBiosciences), a small-molecule ATGL inhibitor, or saline vehicle.
They were then subjected to a basal infusion of [1,1,2,3,3-d5] glycerol,
[U-13C] palmitate, and [3-3H] glucose as described above.
CPT-1 Inhibition
Overnight fasted chow and high-fat-fed rats were treated with intraperitoneal
injections of etomoxir (8 mg 3 kg1) and immediately began an infusion of
[1,1,2,3,3-d5] glycerol, [U-
13C] palmitate, and [3-3H] glucose as described
above.
Adipocyte Morphology and Function
White adipose tissue glucose uptake was measured in basal and clamped
rats following injection of 2-[1-14C] deoxyglucose (Cartee and Bohn, 1995).
Insulin-stimulated WAT lipogenesis and adipocyte cell size were measured
in chow and 4-week high-fat-fed rats as previously described (Kursawe
et al., 2010). To measure IL-6-induced lipolysis, 100-mg WAT samples
were incubated in 5 mM glucose media containing 15 or 25 nM IL-6 to mimic
plasma IL-6 concentrations in vivo in chow and high-fat-fed rats. After 6 hr of
incubation at 37C, NEFA concentrations in the media were measured and
normalized to the total protein content of theWAT sample, measured by Brad-
ford assay.
IL-6 Neutralization
Overnight fasted 4-week high-fat-fed rats were treated with an intraperitoneal
injection of a neutralizing antibody to IL-6 (10 mg/rat, R&D Systems) in saline, or
an equivalent volume of saline. Immediately following the antibody injection,
[1,1,2,3,3-d5] glycerol, [U-
13C] palmitate, and [3-3H] glucose were infused
intra-arterially for themeasurement of lipolysis and hepatic glucose production
as described above.
IL-6 Infusion
A continuous intra-arterial infusion of IL-6 (10 mg/hr1, Sigma) was performed
for 4 hr. After 2 hr of IL-6 infusion, atglistatin (200 mmol/kg1) was injected intra-
venously, and rates of lipolysis and hepatic glucose production were assessed
as described above.
Biochemical Analyses
Plasma glucose concentrations were measured using the YSI 2700 Select
Biochemistry Analyzer, and plasma lactate concentrations by COBAS. Plasma
insulin concentrations were measured by ELISA (Millipore). NEFA concentra-
tions were measured using a Wako kit. Plasma insulin was measured by
radioimmunoassay by the Yale Diabetes Research Core. Plasma FGF-21, adi-
ponectin, corticosterone, epinephrine, norepinephrine, growth hormone, and
inflammatory cytokine concentrations were measured by ELISA (Millipore,
Invitrogen, Abcam, IBL International, IBL International, Life Technologies,
and QIAGEN, respectively).
Tissue Analyses
Liver acetyl CoA concentration and enrichment was measured by liquid
chromatography/mass spectrometry/mass spectrometry (LC-MS/MS) as
described in the Extended Experimental Procedures. Liver glycogen concen-
trationsweremeasured in basal and clamped rats using themethod of Dalrym-
ple and Hamm (1973). Pyruvate carboxylase activity was measured as
previously described (Vatner et al., 2013), with acetyl CoA concentrations
adjusted to match those measured by LC-MS/MS in each group. Liver ATP,
ADP, AMP, NAD, and NADH concentrations were measured by LC-MS/MS
as previously described (Perry et al., 2013).
WAT Macrophage Isolation
WAT tissue was washed with HBSS and then incubated at 37C, shaking
for 60 min in HBSS with 0.5 mg/ml collagenase (Sigma). After washing three
times with HBSS, cell debris was reduced by Histopaque density centrifuga-
tion. The remaining cells were stained with CD11b-PE (eBioscience), and
CD11b+ WAT macrophages were enriched to >90% purity by EasySep PE
positive selection kit (STEMCELL Technologies). Purity and cell number
were confirmed by flow cytometry. WAT macrophage IL-6 and WAT tissue
GM-CSF and TNF-a were measured by ELISA (Life Technologies, Abcam,
and SABiosciences, respectively) and normalized to total protein content
measured by Bradford assay.
Western Blots
Protein expression was measured in mouse and rat liver by western blot, with
antibodies obtained from Cell Signaling Technology (Akt1, Akt2, Akt pSer473,
Foxo1, pyruvate carboxylase, phosphoenolpyruvate carboxykinase, glucose-
6-phosphatase, adipose triglyceride lipase, insulin receptor substrate-1, and
glyceraldehyde 3-phosphate dehydrogenase) or from Santa Cruz Biotech-
nology (CGI-58, peroxisome proliferator-activated receptor gamma, glucose
transporter type 4, and protein phosphatase 1).
Human Studies
The Yale Pathophysiology of Type 2 Diabetes in Obese Youth Study is a long-
term project aimed at examining early alterations in glucose metabolism in
relation to fat patterning in obese adolescents. Specific details of this study
are described in the Extended Experimental Procedures.
Statistical Analyses
Statistical analyses were performed using GraphPad Prism. Comparisons be-
tween two groups were performed by the two-tailed unpaired Student’s t test,
while three groups were compared by ANOVA with Bonferroni’s post hoc test.
Differences were considered significant at p < 0.05. Data are presented as
mean ± SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and one table and can be found with this article online at http://dx.doi.
org/10.1016/j.cell.2015.01.012.
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